Medication info
Crescent Tablet 5 mg (Rosuvastatin Calcium)

Crescent Tablet 5 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Boryung Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/box (10 tablets/PTP x 3), 100 tablets/box (10 tablets/PTP x 10), 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201001041 · Approved 2010.01.29 · Insurance code 641905390

Summary

Main use
Treats dyslipidemia, slows the progression of atherosclerosis, and prevents cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The starting dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased up to a maximum of 20 mg daily. 3. Elderly patients : No dosage adjustment is necessary. 4. Patients with renal impairment : No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Child dose
Ages 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on administering doses greater than 20 mg to pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Boryung Co., Ltd.

Efficacy & effects

Treats dyslipidemia, slows the progression of atherosclerosis, and prevents cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • increased total cholesterol
  • increased LDL-cholesterol
  • increased Apo-B protein levels
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
View approved original text

This medication is helpful when dietary management and exercise are insufficient for patients with primary hypercholesterolemia and mixed dyslipidemia, and it lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is also used as an adjunct to diet in patients with homozygous familial hypercholesterolemia or primary dysbetalipoproteinemia. It is effective in lowering cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia. Additionally, it helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in adults with cardiovascular disease risk factors. It is widely used to improve cardiovascular health due to these efficacies.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The starting dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased up to a maximum of 20 mg daily. 3. Elderly patients : No dosage adjustment is necessary. 4. Patients with renal impairment : No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Child dose

Ages 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on administering doses greater than 20 mg to pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication is contraindicated for certain patients. For example, patients allergic to any component of this medication, those with active liver disease, those with muscle disorders, and those with severe renal dysfunction should not take this medication. Pregnant or breastfeeding women, as well as women of childbearing age not using appropriate contraception, should also avoid this medication. If administered to women of childbearing age, the potential for pregnancy and risks to the fetus must be considered. Additionally, caution is required in patients vulnerable to muscle disorders, those with hypothyroidism or a family history, alcoholics, and those concomitantly taking specific medications. This medication contains lactose and should not be administered to patients with lactose intolerance or certain genetic metabolic disorders. Patients with a history of excessive alcohol consumption or liver disease should have their liver function tested before use and regularly monitor liver enzyme levels during treatment. If symptoms such as muscle pain, weakness, or cramps occur, patients should immediately inform healthcare providers and may need blood tests to check for muscle damage. Special caution is needed for the elderly, patients with reduced renal function, and patients taking certain other medications due to the heightened risk of muscle-related side effects. While this medication is not generally known to significantly affect driving ability or machine operation, caution is advised as dizziness may occur. Serious side effects such as abnormal liver function, increased risk of diabetes, and rarely severe skin reactions or interstitial lung disease may occur, necessitating immediate consultation with a physician if unusual symptoms arise. This medication may interact with other drugs, so patients should inform healthcare providers of any other medications they are taking, especially when used in combination with specific antiviral agents, antifungals, immunosuppressants, or fibrate drugs, as risks may increase. Pregnant or breastfeeding individuals should not use this medication, and women who may become pregnant should use appropriate contraceptive methods. In case of overdose, there is no specific antidote; patients should seek immediate medical attention for symptomatic treatment and evaluation.

Side effects

Angioedema, hypersensitivity reactions, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, drug-induced exfoliative dermatitis, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, increased CK, increased AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent air or moisture ingress. It is best stored at room temperature between 1 degree Celsius and 30 degrees Celsius, avoiding areas that are too hot or too cold.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/box (10 tablets/PTP x 3), 100 tablets/box (10 tablets/PTP x 10), 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.